Yeah, so at the moment, there are clearly clinicians with some biases towards active surveillance or towards adjuvant chemotherapy. And we hope that a microRNA 371 can optimize that decision-making. So if it’s positive, given that we’ve demonstrated that it increases the risk of recurrence, that is the population that may benefit from adjuvant chemotherapy, but we need to design clinical trials to prove that...
Yeah, so at the moment, there are clearly clinicians with some biases towards active surveillance or towards adjuvant chemotherapy. And we hope that a microRNA 371 can optimize that decision-making. So if it’s positive, given that we’ve demonstrated that it increases the risk of recurrence, that is the population that may benefit from adjuvant chemotherapy, but we need to design clinical trials to prove that. In the patients who are negative for microRNA 371, we can see that their risk of recurrence is very low. So the question there would be, can we kind of reduce the number of CT scans and imaging that we’re doing as part of surveillance?
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
